The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
May. 27, 2025

Filed:

May. 03, 2023
Applicant:

Pfizer Inc., New York, NY (US);

Inventors:

Brian Stephen Gerstenberger, Cambridge, MA (US);

Andrew Christopher Flick, Carlsbad, CA (US);

Daniel Wei-Shung Kung, Salem, CT (US);

Vincent Michael Lombardo, Carmel, IN (US);

James John Mousseau, Norwich, CT (US);

Philippe Marcel Nuhant, Dorchester, MA (US);

Ralph Pelton Robinson, Jr., Gales Ferry, CT (US);

Daniel Copley Schmitt, Westerly, RI (US);

Mark Edward Schnute, Acton, MA (US);

Atli Thorarensen, Stow, MA (US);

John Isidro Trujillo, Ledyard, CT (US);

Rayomand Jal Unwalla, Bedford, MA (US);

Huixian Wu, East Lyme, CT (US);

Assignee:

Pfizer Inc., New York, NY (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07D 413/14 (2006.01); A61P 29/00 (2006.01); C07D 401/12 (2006.01); C07D 401/14 (2006.01); C07D 405/14 (2006.01); C07D 413/12 (2006.01); C07D 417/12 (2006.01); C07D 417/14 (2006.01); C07F 9/6558 (2006.01);
U.S. Cl.
CPC ...
C07D 413/14 (2013.01); A61P 29/00 (2018.01); C07D 401/12 (2013.01); C07D 401/14 (2013.01); C07D 405/14 (2013.01); C07D 413/12 (2013.01); C07D 417/12 (2013.01); C07D 417/14 (2013.01); C07F 9/65583 (2013.01);
Abstract

The present invention relates to N-substituted-dioxocyclobutenylamino-3-hydroxy-picolinamide compounds of Formulae (IA and 1B) or a pharmaceutically acceptable salt or hydrate thereof, that inhibit CC chemokine receptor 6 (CCR6), pharmaceutical compositions containing these compounds, and the use of these compounds for treating or preventing diseases, conditions, or disorders ameliorated by inhibition of CCR6.


Find Patent Forward Citations

Loading…